Endovascular Stenting of Medically Refractory ICASD (Clinical and Sonographic Study)

Endovascular Stenting of Medically Refractory Intracranial Arterial Stenotic (ICAS) Disease (Clinical and Sonographic Study)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04393025

Acronym

VasIntervent

Enrollment

Registered

2020-05-19

Start date

2016-06-30

Completion date

2019-06-30

Last updated

2020-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Ischemic

Brief summary

Cerebral Endovascular Stenting of medically refractory Intracranial Stenotic Blood Vessels with Recurrent Ischemic Strokes patients

Detailed description

Fifty patients were enrolled with 25 underwent Intracranial Stenting 25 received optimal medicall treatment without stenting and comparative study of primary outcome was conducted

Interventions

DEVICEIntracranial Stenting by Intracranial Stent Device

Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted

DRUGOptimum medical treatment

Optimum Medical treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Two armed medical study

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients age between 30-80 years. 2. Symptomatic ICAS: presented with TIA or stroke, attributed to 70%-99% stenosis of a major intracranial artery: Internal carotid artery (ICA), middle cerebral artery (MCA) \[M1segment\], vertebral artery (VA), or basilar artery (BA). 3. Patient with recurrent TIA or stroke despite medical therapy, including anti-coagulation or antiplatelet and control of all vascular risk factors (DM, HTN and Hyperlipidemia).

Exclusion criteria

1. Patients previously stented at the target lesion or had extracranial stenosis. 2. Patient with acute stroke (within two weeks from the onset). 3. Complete occlusion of the artery on the imaging assessment. 4. Massive cerebral infarction (more than half the MCA territory), intracranial hemorrhage, epidural or subdural hemorrhage, and intracranial brain tumor on CT or MRI scans. 5. Contraindications to antithrombotic and/or anticoagulant therapies.

Design outcomes

Primary

Measure	Time frame	Description
Clinical improvement of IC stented patients in comparison to medically treated	3 months	clinical assessment by National Institute of Health Stroke Scale (NIHSS) for clinical impr
Functional improvement of IC stented patients in comparison to medically treated	3 months	Functional assessment by modified Rankin Scale (mRS) for functional improvement
Blood flow velocity accrossed Stenotic Large IC Vessels in comparison to medically treated	3 months	Transcranial doppler (TCD) assessment of Mean Flow Velocity (MFV) across IC vessels

Secondary

Measure	Time frame	Description
No Recurrent Ischemic stroke in stented ICSD patients	6 months	Clinical Assessment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026